New independent data from Thomas Jefferson University in Philadelphia, USA, has demonstrated that the use of negative pressure therapy using Prevena incision management system may reduce the rate of major wound complications and associated costs following vascular groin surgery in high-risk patients. The results were presented at the 2017 Society for Vascular Surgery annual meeting (SVS; May 31–June 3, San Diego, USA).
Getinge has announced the opening of a new modern hybrid operating room (OR) in the Experience Center in Rastatt, Germany. The Hybrid OR will enable intraoperative 2D and 3D imaging during minimally invasive surgery.
The Society for Vascular Surgery (SVS) executive board has established a task force to explore developing a vascular certification program for inpatient and outpatient care settings.
Atherectomy for occlusive disease in the femoral-popliteal and tibial-peroneal segments for claudication in outpatient settings may result in outcomes worse than the natural history of the disease, according to data presented at the 2017 Vascular Annual Meeting (VAM; 30 May–3 June, San Diego, USA).
Philips has announced the relaunch of its Pioneer Plus catheter, “the first and only re-entry device with intravascular ultrasound (IVUS) capabilities and needle deployment designed to assist arterial vessel intervention,” according to a company press release.
Philips has completed the acquisition of Spectranetics. Spectranetics’ financial results will be consolidated as part of Philips’ Image-Guided Therapy business group as of August 9, 2017.
Results published in Diabetes Care demonstrate that the Podimetrics SmartMat detected as many as 97% of developing nontraumatic plantar foot ulcers on average five weeks before they presented clinically.
Type B aortic dissection (TBAD) patients exhibit poor adherence to best medical therapy, which may play a part in the high levels of aortic morbidity and mortality seen in this patient cohort, according to research presented by Colin Bicknell (London, UK) at the 2017 Critical Issues meeting (19–20 May, Nuremberg, Germany).
LimFlow announced on 1 August 2017 publication of positive results from the pilot study of the LimFlow Percutaneous Deep Vein Arterialization System (pDVA) in the July issue of the Journal of Endovascular Therapy. The paper is entitled “Midterm Outcomes from a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia.” The LimFlow System is a novel, purely percutaneous device for the treatment of end-stage critical limb ischaemia (CLI) when all other revascularisation efforts have been exhausted.
Positive two-year clinical data from Endologix’ Nellix EVAS FORWARD investigative device exemption trial have been presented at the Society of Vascular Surgery (SVS; 31 May–3 June) 2017 annual meeting. The trial prospectively enrolled patients with abdominal aortic aneurysms (AAA) who were treated with the Nellix endovascular aneurysm sealing system.
The US Patent and Trademark Office has granted Ra Medical Systems a broad patent (number 9700655) that covers Ra Medical Systems’ DABRA catheter for cardiovascular disease treatment. The inventors include Ra Medical Systems director of research and development, James Laudenslager, and chief executive officer and chief technical officer, Dean Irwin. DABRA recently received FDA market clearance and is now available in the USA and Europe.
Shockwave Medical has announced two milestones for its Lithoplasty system for the treatment of calcified plaque in patients with peripheral artery disease (PAD): enrolment of the first patient in the global DISRUPT PAD III clinical trial at the Medical University of Graz, Austria, and the treatment of the first patient in a commercial case in the USA, at Pottstown Memorial Medical Center in Pottstown.
Silk Road Medical has received US$47 million in new funding led by new investors Norwest Venture Partners and funds managed by Janus Capital Management LLC. Existing investors Warburg Pincus, The Vertical Group, and CRG also participated in the round. The new financing will be used to support the company’s rapid commercial growth of its proprietary ENROUTE family of products for transcarotid artery revascularisation (TCAR) procedures.
Spectranetics has announced receipt of US Food and Drug Administration (FDA) pre-market approval of the Stellarex drug-coated balloon (DCB), designed to restore and maintain blood flow to the superficial femoral and popliteal arteries in patients with peripheral artery disease (PAD).
A US study based on the largest representative sample of e-cigarette users to date has provided evidence that e-cigarette use is associated with an increase in smoking cessation at the population level.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos